WallStSmart
DWTX

Dogwood Therapeutics, Inc.

NASDAQ: DWTX · HEALTHCARE · BIOTECHNOLOGY

$1.94
+3.19% today

Updated 2026-09-11

Market cap
$87.70M
P/E ratio
1.37
P/S ratio
EPS (TTM)
$1.89
Dividend yield
52W range
$1 – $10
Volume
0.1M

Dogwood Therapeutics, Inc. (DWTX) Stock Valuation Analysis

Fair value estimate, historical valuation range, and quality signals for DWTX.

WallStSmart Verdict
Overvalued

Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.

Smart Value Score: 23 / 100
P/E (TTM)
1.4x
vs 5Y median of 1.3x
PEG
Margin of Safety
DCF limited for this profile
EV / EBITDA
0.0x

DWTX historical valuation range

Where current P/E sits in DWTX's own 5Y range.

NOW
1.2x
5Y Low
1.3x
25th
1.3x
Median
1.4x
75th
1.6x
5Y High
DWTX is trading more expensive than 75% of the last 5Y.
75th percentile · Historically expensive

DWTX intrinsic value (DCF)

DCF-based fair value estimate vs current market price.

DCF has limited applicability for DWTX

Standard discounted cash flow models produce unreliable output for unprofitable or near-breakeven companies. Revenue-based multiples such as P/S and EV/Sales, combined with the historical valuation position above, give a more reliable read for this stock.

Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.

DWTX valuation signals

Quick-read green flags, caution flags, and risks based on current metrics.

!
P/E in mid-range
P/E sits at the 75th percentile of the 5Y range. Neither cheap nor rich historically.
!
DCF limited applicability
Company profile produces unstable DCF output. Lean on P/S, EV/Sales, and historical valuation position instead of intrinsic value for this stock.
Weak financial quality
Piotroski F-Score of 1/9 suggests deteriorating fundamentals. Valuation requires closer scrutiny.

P/E Ratio — History

Current: 1.37x

P/S Ratio — History

Current: 0.00x

No historical P/S data available

Is DWTX overvalued in 2026?

Dogwood Therapeutics, Inc. (DWTX) currently trades at $1.94 per share with a market capitalization of $87,701,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 23/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.

The stock trades at a P/E ratio of 1.4x, above its 5-year median of 1.3x.

Looking at its own history, DWTX is currently trading more expensive than 75% of the last 5Y on P/E. This places it in the 75th percentile of its historical range, a reasonable but unremarkable position.

A standard DCF model does not produce reliable output for DWTX under current conditions. For unprofitable or near-breakeven companies, revenue-based multiples such as EV/Sales and historical P/S percentile are more informative than intrinsic value calculations.

Financial quality is a concern. The Piotroski F-Score of 1/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.

Bottom line: DWTX appears richly valued on our framework, with a Smart Value Score of 23/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.

Frequently asked questions

Is DWTX overvalued?

DWTX scores 23/100 on our Smart Value Score (Grade F), a weak overall profile. A standard DCF is unreliable here given the profitability profile, so valuation leans on revenue-based measures like EV/Sales and the P/S percentile below.

What is DWTX's fair value?

A standard DCF is unreliable for DWTX given its current profitability profile. Revenue-based approaches like EV/Sales or the historical P/S percentile are more informative for this stock.

What P/E ratio does DWTX trade at?

DWTX trades at a P/E of 1.4x on trailing twelve-month earnings, against a 5-year median of 1.3x. P/E is what you pay per dollar of profit, and sitting above its own median means the stock is pricier than usual relative to its earnings.

Is DWTX a buy based on valuation?

Our Smart Value rating for DWTX is Strong Sell, from a Smart Value Score of 23/100 that blends growth, quality, and valuation. The profile skews cautious, and a better price or clearer operating improvement would strengthen the case. This is research to inform your decision, not personalized financial advice.

How does DWTX's valuation compare to its history?

On P/E, DWTX sits in the 75th percentile of its own 5Y range, historically expensive relative to where it has traded. A high percentile means today's multiple is near the top of its historical band.

What is DWTX's Smart Value Score?

DWTX's Smart Value Score is 23/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.